Recommended Topic Related To:

Luvox

"Dec. 5, 2011 -- Newer antidepressants are all about equally effective, according to a new analysis, but that doesn't mean they work the same way for everyone.

"Contrary to drug industry claims, scientific evidence does not support the"...

Luvox

Indications
Dosage
How Supplied

INDICATIONS

Obsessive-Compulsive Disorder

Fluvoxamine Maleate (fluvoxamine maleate) Tablets are indicated for the treatment of obsessions and compulsions in patients with obsessive compulsive disorder (OCD), as defined in DSM-III-R or DSM-IV. The obsessions or compulsions cause marked distress, are time-consuming, or significantly interfere with social or occupational functioning.

Obsessive compulsive disorder is characterized by recurrent and persistent ideas, thoughts, impulses or images (obsessions) that are ego-dystonic and/or repetitive, purposeful, and intentional behaviors (compulsions) that are recognized by the person as excessive or unreasonable.

The efficacy of Fluvoxamine Maleate (fluvoxamine maleate) Tablets was established in four trials in outpatients with OCD: two 10-week trials in adults, one 10-week trial in pediatric patients (ages 8-17), and one maintenance trial in adults. (See Clinical Studies.)

DOSAGE AND ADMINISTRATION

Adults

The recommended starting dose for Fluvoxamine Maleate (fluvoxamine maleate) Tablets in adult patients is 50 mg, administered as a single daily dose at bedtime. In the controlled clinical trials establishing the effectiveness of Fluvoxamine Maleate (fluvoxamine maleate) Tablets in OCD, patients were titrated within a dose range of 100 to 300 mg/day. Consequently, the dose should be increased in 50 mg increments every 4 to 7 days, as tolerated, until maximum therapeutic benefit is achieved, not to exceed 300 mg per day. It is advisable that a total daily dose of more than 100 mg should be given in two divided doses. If the doses are not equal, the larger dose should be given at bedtime.

Pediatric Population (children and adolescents)

The recommended starting dose for Fluvoxamine Maleate (fluvoxamine maleate) Tablets in pediatric populations (ages 8-17 years) is 25 mg, administered as a single daily dose at bedtime. In a controlled clinical trial establishing the effectiveness of Fluvoxamine Maleate (fluvoxamine maleate) Tablets in OCD, pediatric patients (ages 8-17) were titrated within a dose range of 50 to 200 mg/day. Physicians should consider age and gender differences when dosing pediatric patients. The maximum dose in children up to age 11 should not exceed 200 mg/day. Therapeutic effect in female children may be achieved with lower doses. Dose adjustment in adolescents (up to the adult maximum dose of 300 mg) may be indicated to achieve therapeutic benefit. The dose should be increased in 25 mg increments every 4 to 7 days, as tolerated, until maximum therapeutic benefit is achieved. It is advisable that a total daily dose of more then 50 mg should be given in two divided doses. If the two divided doses are not equal, the larger dose should be given at bedtime.

Elderly or Hcpatically Impaired Patients

Elderly patients and those with hepatic impairment have been observed to have a decreased clearance of fluvoxamine maleate (fluvoxamine maleate) . Consequently, it may be appropriate to modify the initial dose and the subsequent dose titration for these patient groups.

Pregnant Women During the Third Trimester

Neonates exposed to Fluvoxamine Maleate (fluvoxamine maleate) Tablets and other SSRIs or SNRIs late in the third trimester have developed complications requiring prolonged hospitalization, respiratory support, and tube feeding and may be at risk for persistent pulmonary hypertension of the newborn (PPHN). (See Use In Specific Populations.) When treating pregnant women with Fluvoxamine Maleate (fluvoxamine maleate) Tablets during the third trimester, the physician should carefully consider the potential risks and benefits of treatment. The physician may consider tapering Fluvoxamine Maleate (fluvoxamine maleate) Tablets in the third trimester.

Switching Patients To or From a Monoamine Oxidase Inhibitor

At least 14 days should elapse between discontinuation of an MAOI and initiation of therapy with Fluvoxamine Maleate (fluvoxamine maleate) Tablets. Similarly, at least 14 days should be allowed after stopping Fluvoxamine Maleate (fluvoxamine maleate) Tablets before starting an MAOI.

Maintenance/Continuation Extended Treatment

It is generally agreed that obsessive compulsive disorder requires several months or longer of sustained pharmacologic therapy. The benefit of maintaining patients with OCD on Fluvoxamine Maleate (fluvoxamine maleate) Tablets after achieving a response for an average duration of about 4 weeks in a 10-week single-blind phase during which patients were titrated to effect was demonstrated in a controlled trial [see Clinical Trials]. The physician who elects to use Fluvoxamine Maleate (fluvoxamine maleate) Tablets for extended periods should periodically re-evaluate the long-term usefulness of the drug for the individual patient.

Discontinuation of Treatment with Fluvoxamine Maleate (fluvoxamine maleate) Tablets

Symptoms associated with discontinuation of other SSRIs or SNRIs have been reported. (See WARNINGS AND PRECAUTIONS.) Patients should be monitored for these symptoms when discontinuing treatment. A gradual reduction in the dose rather than abrupt cessation is recommended whenever possible. If intolerable symptoms occur following a decrease in the dose or upon discontinuation of treatment, then resuming the previously prescribed dose may be considered. Subsequently, the physician may continue decreasing the dose but at a more gradual rate.

HOW SUPPLIED

Dosage Forms and Strengths

Fluvoxamine Maleate (fluvoxamine maleate) Tablets are available as:

Tablets 25 mg: unscored, white, elliptical, film-coated (debossed "1222" on one side)

Tablets 50 mg: scored, yellow, elliptical, film-coated (debossed "1225" on one side and scored on the other)

Tablets 100 mg: scored, beige, elliptical, film-coated (debossed "1221" on one side and scored on the other)

Fluvoxamine Maleate (fluvoxamine maleate) Tablets are available in the following strengths, colors, imprints, and presentations:

Tablets 25 mg: unscored, white, elliptical, film-coated (debossed "1222" on one side)

Bottles of 100......................................NDC 62559-158-01

Tablets 50 mg: scored, yellow, elliptical, film-coated (debossed "1225" on one side and scored on the other)

Bottles of 100......................................NDC 62559-159-01

Tablets 100 mg: scored, beige, elliptical, film-coated (debossed "1221" on one side and scored on the other)

Bottles of 100......................................NDC 62559-160-01

Storage

Keep out of reach of children.

Fluvoxamine Maleate (fluvoxamine maleate) Tablets should be protected from high humidity and stored at 25 °C (77°F); excursions permitted to 15° to 30°C (59° to 86°F) [see USP Controlled Room Temperature].

Dispense in tight containers.

Manufactured by: ANI Pharmaceuticals, Inc Baudette, MN 56623. Revised 3/2011

Last reviewed on RxList: 5/9/2011
This monograph has been modified to include the generic and brand name in many instances.

Indications
Dosage
How Supplied
A A A

Luvox Tablets - User Reviews

Luvox Tablets User Reviews

Now you can gain knowledge and insight about a drug treatment with Patient Discussions.

Here is a collection of user reviews for the medication Luvox Tablets sorted by most helpful. Patient Discussions FAQs

Report Problems to the Food and Drug Administration

 

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.


Emotional Wellness

Get tips on therapy and treatment.